News Search Results
Apr 02, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently no longer agrees
More news about: Pomerantz LLP
Apr 01, 2026, 19:11 ET QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food
More news about: THE ROSEN LAW FIRM, P. A.
Mar 31, 2026, 09:00 ET Huntington National Bank Selects the SEI Wealth Platform℠
and reinforces their advice-led model. With SEI's expansive inventory of APIs and robust data cloud solution, SWP will seamlessly integrate with Huntington's core banking systems to unlock new growth opportunities and deliver consistent, scalable, and enhanced experiences for their private bank and high-net-worth
More news about: SEI Investments Company
Mar 30, 2026, 13:00 ET uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's Huntington's disease gene therapy drug.Investor Action: Contact
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 27, 2026, 15:30 ET QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food
More news about: THE ROSEN LAW FIRM, P. A.
Mar 26, 2026, 10:12 ET Huntington Bank Awards More Than 250 West Virginia Educators Year-long Professional Development Experience
Educators from 12 counties selected to participate in Huntington's Ignite the Classroom InitiativeCHARLESTON, W.Va., March 26, 2026 /PRNewswire/ -- The Huntington National Bank (Huntington) has
More news about: Huntington Bank
Mar 26, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently no longer agrees
More news about: Pomerantz LLP
Mar 26, 2026, 08:30 ET Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
controlled (tardive dyskinesia). involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions. It is not known
More news about: Neurocrine Biosciences, Inc.
Mar 24, 2026, 19:17 ET uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed; April 13, 2026, Lead Plaintiff Deadline
Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's Huntington's disease gene therapy drug.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 24, 2026, 09:00 ET Huntington Bank Introduces Team Huntington Golf Ambassadors
The roster builds on Huntington's recently announced
More news about: Huntington National Bank
Mar 23, 2026, 20:55 ET QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food
More news about: THE ROSEN LAW FIRM, P. A.
Mar 19, 2026, 17:40 ET Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline
Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's Huntington's disease gene therapy drug.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 19, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently no longer agrees
More news about: Pomerantz LLP
Mar 18, 2026, 15:43 ET Genome Canada and Ontario Genomics Award Specific Biologics and Western University $1.8 Million Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company's Dualase®-based Therapeutics
ALS to create new drug candidates for patients with high morbidity and mortality genetic diseases, including other repeat expansion diseases like Huntington's Disease."This funding supports a natural evolution of the Dualase® platform," said Dr. Brent Stead, CEO of Specific. "By integrating
More news about: Specific Biologics Inc.
Mar 18, 2026, 15:43 ET Genome Canada and Ontario Genomics Award Specific Biologics and Western University $1.8 Million Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company's Dualase®-based Therapeutics
ALS to create new drug candidates for patients with high morbidity and mortality genetic diseases, including other repeat expansion diseases like Huntington's Disease."This funding supports a natural evolution of the Dualase® platform," said Dr. Brent Stead, CEO of Specific. "By integrating
More news about: Specific Biologics Inc.
Mar 17, 2026, 16:05 ET Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
Mar 17, 2026, 09:00 ET Huntington Bank Introduces Roster of Collegiate Golf Ambassadors
Initiative reinforces Huntington's commitment to supporting young athletes by investing in potentialCOLUMBUS, Ohio, March 17, 2026 /PRNewswire/ -- The Huntington National Bank ("Huntington") announced
More news about: Huntington National Bank
Mar 16, 2026, 15:05 ET QURE INVESTOR ALERT: uniQure Faces Securities Class Action Over AMT-130 Clinical Trial Design - Hagens Berman
complaint alleges that uniQure's leading drug candidate is AMT-130, a novel gene therapy being developed to slow the progression of Huntington's disease.The complaint alleges that throughout the Class Period defendants misrepresented and failed to disclose that:
More news about: Hagens Berman Sobol Shapiro LLP
Mar 16, 2026, 01:23 ET QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food
More news about: THE ROSEN LAW FIRM, P. A.
Mar 13, 2026, 14:34 ET uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's Huntington's disease gene therapy drug.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 12, 2026, 15:24 ET QURE ALERT: FDA Reportedly Accuses uniQure of Pushing "Distorted" and "Manipulated" Data For "Failed" AMT-130 Drug Amid Pending Securities Class Action - Hagens Berman
for agency approval." The therapy at issue is uniQure's lead gene therapy candidate, AMT-130, which is being developed to slow the progression of Huntington's disease.Worse, the WSJ reported "[t]he official also said a Uniqure executive had mischaracterized the FDA's request for how to compare
More news about: Hagens Berman Sobol Shapiro LLP
Mar 12, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently no longer agrees
More news about: Pomerantz LLP
Mar 10, 2026, 16:01 ET Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
Mar 10, 2026, 10:25 ET Skyhawk Therapeutics Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington's Disease
therapies for neurological disorders, including for chorea associated with Huntington's disease (HD) with AUSTEDO®. SKY-0515 is Skyhawk's lead program and is being developed as a potential disease-modifying therapy for Huntington's disease. "Skyhawk may receive accelerated approval for SKY-0515
More news about: Skyhawk Therapeutics
Mar 10, 2026, 10:02 ET Skyhawk Therapeutics Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington's Disease
therapies for neurological disorders, including for chorea associated with Huntington's disease (HD) with AUSTEDO®. SKY-0515 is Skyhawk's lead program and is being developed as a potential disease-modifying therapy for Huntington's disease.
More news about: Skyhawk Therapeutics